AI revolutionizes palliative oncology by enhancing prognostication, symptom management, and personalized care for patients with hematologic malignancies.
Plinabulin in combination with pegfilgrastim reduced the incidence of chemotherapy-induced neutropenia, compared with pegfilgrastim alone, in patients with breast cancer undergoing chemotherapy with docetaxel, doxorubicin, and cyclophosphamide.
The panel discusses adverse effects associated with stereotactic body radiation therapy, and the Oncology Brothers provide a recap of the entire discussion.
The clinical quandary by Langer et al discusses a contralateral late relapse of the original right nonseminomatous germ cell tumors.
Explore the differences between bispecific antibodies and CAR T-cell therapy, highlighting their unique benefits and administration processes in cancer treatment.
“Be courageous: Your work will be recognized, and everything is about [the] work in the end.”
Lisa Sprod, PhD, MPH, provides perspective on a cancer-related fatigue assessment tools.
Experts at Yale Cancer Center highlight ongoing trials intended to improve outcomes across mantle cell lymphoma, T-cell lymphoma, and other populations.
Jose Sandoval Sus, MD, discussed standard CAR T-cell therapies in patients across multiple high-risk lymphoma indications.
A multitude of factors contributes to cancer disparities. Addressing these disparities among racial/ethnic minority populations with blood cancers requires multilevel models of the interactions between relevant factors and the performance of translational research that uses knowledge of cancer biology to develop and test the feasibility of interventions that can impact human endpoints. To be effective, efforts should be made to advance these research findings to applications that can transform clinical practice and health care delivery. We reviewed the literature to define a framework for overcoming disparities for patients with hematologic malignancies and to improve patient enrollment in clinical trials.
Registered nurses discuss research related to agents like ciltacabtagene autoleucel presented at the 2024 Oncology Nursing Society Congress.
Immunocompromised individuals face ongoing COVID-19 risks despite vaccination, highlighting the need for tailored public health strategies and innovative therapies.
A systematic review of reported clinical cases and treatment strategies was performed to better understand the prognostic factors and to develop the best possible treatment option for a 16-year-old patient diagnosed with a malignant triton tumor in the lower extremity with distant metastases in the lungs.
A leading expert in the field of esophageal cancers discussed his upcoming research on cabozantinib combined with pembrolizumab to treat gastroesophageal adenocarcinoma at the 2021 ASCO Gastrointestinal Cancers Symposium.
Key opinion leaders summarize essential takeaways and highlight unmet needs in the hepatocellular carcinoma treatment landscape.
A systematic review of reported clinical cases and treatment strategies was performed to better understand the prognostic factors and to develop the best possible treatment option for a 16-year-old patient diagnosed with a malignant triton tumor in the lower extremity with distant metastases in the lungs.
Suneel K. Kamath, MD, et al investigated exceptional responders and the correlation of nonsynonymous mutations for patients with advanced pancreatic cancer.
Jason M. Hafron, MD, CMO, and Oliver Sartor, MD, share their approach for the optimal management of mCRPC through genetic testing.
This study investigated the biomarker potential of glutamine among known prognostic variables in localized prostate cancer.
Brett L. Ecker, MD, discusses the importance of multidisciplinary collaboration in improving patient outcomes in neuroendocrine tumors.
Qianyue Deng, MD, and colleagues examine the efficacy of thoracic radiotherapy for the treatment of unresectable non-small cell lung cancer.